EDTA, pseudothrombocytopenia

EDTA, pseudothrombocytopenia, 21.250 Endothelin receptor antagonists, in hypertension, 26.233 Enzyme inhibitors, 15.337... 

Bizzaro N., Brandalise M. EDTA-dependent pseudothrombocytopenia. Association with antiplatelet and antiphospholipid antibodies. Am J Clin Pathol 1995 103, 103-7. 

Adverse effects. Haemorrhage occurs but is less of a problem with low doses of heparin it remains a particular risk in patients treated after failed fibrinol5 c therapy for acute myocardial infarction. Platelet transfusion after cessation of abciximab is necessary for refractory or life threatening bleeding. After transfusion, the antibody redistributes to the transfused platelets, reduces the mean level of receptor blockade and improves platelet function. Thrombocytopenia may occur from 1 hour to days after commencing treatment in up to 1% of patients. This necessitates platelet counts at 2-4 hours and then daily if severe, therapy must be stopped and, if necessary, platelets transfused. EDTA-induced pseudothrombocytopenia has been reported and a low platelet count should prompt examination of a blood film for agglutination before therapy is stopped. 

Maniscalchi T, Corbo A, Fighola G, Vaccaro S, Cicatello C, Di Rosa S. EDTA-induced pseudothrombocytopenia. Policlin Sez Med 1996 103 7-12. 

Allerheiligen D, Houston R, Vermedahl B. EDTA-induced pseudothrombocytopenia. J Am Board Fam Pract 1996 9(3) 212-14. 

Berkman N, Michaeli Y, Or R, Eldor A. EDTA-dependent pseudothrombocytopenia a clinical study of 18 patients and a review of the literature. Am J Hematol 1991 36(3) 195-201. 

Foresti V, Parisio E, Tronci M, Casati O, Zubani R, Pedretti D. Pseudothrombocitopenia da EDTA. [EDTA-induced pseudothrombocytopenia.] Recenti Prog Med 1990 81(10) 661-2. 

Pestana D, Marcote C, de Castro MF. EDTA-dependent pseudothrombocytopenia in a preoperative patient. Acta Anaesthesiol Scand 1992 36(4) 328-30. 

Germing U, Giagounidis A, Sohngen D, Schneider W. EDTA-induced pseudothrombocytopenia a case report. Z Allgmed 1998 740 891. ... 

Pseudothrombocytopenia, defined as in vitro platelet aggregation in blood anticoagulated with ethylenediaminetetraacetic acid (EDTA), is clinically insignificant, but it must also be differentiated from thrombocytopenia induced by abciximab. In this case, microscopic examination of a peripheral blood smear, along with repeated platelet counts in citrate-anticoagulated blood samples, makes the distinction possible. ... 

Stiegler H, Fischer Y, Steiner S, et al. Sudden onset of EDTA-dependent pseudothrombocytopenia after therapy with the glycoprotein Ilb/IIIa antagonists c7E3 Fab. Ann Hematol 2000 79 161-164. 

Hematologic Cases of pseudothrombocytopenia due to EDTA continue to be reported [30, 31 ]. In 49 Chinese patients with cancers in whom the effect occurred there was no relation to sex, concurrent hypertension or diabetes, or cancer type [32 ]. 

Akbayram S, Dogan M, Akgun C, Caksen H, Oner AF. EDTA-dependent pseudothrombocytopenia in a child. Clin Appl Thromb Hemost 2011 17(5) 494-6. 

Wenzel F, Lasshofer R, Rox J, Fischer J, Giers G. Transient appearance of postoperative EDTA-dependent pseudothrombocytopenia in a patient after gastrectomy. Platelets 2011 22(1) 72. ... 

EDTA is well recognised to induce pseudothrombocytopenia (PTCP) caused by platelet aggregation and EDTA-dependent antibodies [79, 80 ]. 

Saigo K, Sakota Y, Masuda Y. EDTA-dependent pseudothrombocytopenia clinical aspects and laboratory tests. Rinsho Byori July 2005 53(7) 646-53. 

Ohno N, Kobayashi M, Hayakawa S, Utsimomiya A, Karakawa S. Transient pseudothrombocytopenia in a neonate transmission of a maternal EDTA-dependent anticoagulant. Platelets 2012 23(5) 399-400. 

Lippi G, Plebani M. EDTA-dep>endent pseudothrombocytopenia further insights and recommendations for prevention of a clinically threatening artifact. Clin Chem Lab Med August 2012 50(8) 1281-5. 

---